<DOC>
	<DOCNO>NCT01167933</DOCNO>
	<brief_summary>The purpose study - compare single dose bioavailability Simvastatin 80 mg tablet Zocor® 80 mg tablet MercK &amp; Co. Inc , USA healthy subject feed condition - monitor adverse event ensure safety subject .</brief_summary>
	<brief_title>Bioequivalence Study Simvastatin Tablets , 80 mg Dr. Reddy 's Under Fed Conditions</brief_title>
	<detailed_description>A randomized , two-treatment , two-period , two-sequence , single dose , crossover bioequivalence study Simvastatin 80 mg tablet Dr. Reddy 's Laboratories Limited compare Zocor® 80 mg tablet Merck &amp; Co. Inc. , USA healthy , adult , human subject feed condition .</detailed_description>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Subjects provide write informed consent . Subjects must healthy adult within 1845 year age ( inclusive ) weigh least 50 kg . Subjects must within ±10 % ideal body weight relation height accord Life Insurance Corporation India heightweight chart nonmedical case . Subjects must normal health determine medical history physical examination perform within 15 day prior ' commencement study . Have normal ECG , Xray vital sign . Availability subject entire study period willingness adhere protocol requirement evidence write informed consent . If subject female volunteer child bear potential practicing acceptable method birth control duration study judge investigator ( ) , condom , foam , jelly , diaphragm , intrauterine device , abstinence . postmenopausal least 1 year . surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy perform subject ) No female volunteer turn site participate study . Bioequivalence study usually conduct healthy adult subject order ass compare pharmacokinetic profile test reference formulation uniform condition . Therefore essential exclude subject show abnormality respect health parameter . Subjects exclude participate study base certain criterion . These criterion make order safeguard health subject enrol study . Subjects incapable understanding informed consent . Subjects BP≤90/60 BP≥140/90 History hypersensitivity idiosyncratic reaction Simvastatin . Any evidence impairment renal , hepatic , cardiac , lung gastrointestinal , endocrine , immunologic , neurologic haematologic function . Regular smoker smoke ten cigarette daily difficulty abstain smoke duration study period . Subjects take counter prescribed medication , include enzyme modifying drug systemic medication within past 30 day prior start clinical period . History psychiatric illness , may impair ability provide write , informed consent . Subjects history alcohol substance abuse within last 5 year . Subjects clinically significant abnormal value laboratory parameter . Subjects participate clinical investigation use experimental drug bleed 350 mL past 3 month . Subjects test positive screening Human Immunodeficiency Virus , Hepatitis B Surface Antigen Hepatitis C Virus Subjects positive urine screen drug abuse . Any subject Simvastatin contraindicate medical reason . Subjects use drug substance herbal preparation know strong inhibitor CYP.enzymes ( formerly know cytochrome P450 enzyme ) within 14 day prior first dose . Female volunteer demonstrate positive pregnancy screen . Female volunteer arecurrently breastfeed . No female volunteer report study site participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Crossover</keyword>
	<keyword>Simvastatin</keyword>
</DOC>